Indicated for: prevention and treatment of thromboembolism
Route of administration: oral
Substance: edoxaban (anticoagulant)
ATC: B01AF03 (Blood and blood forming organs | Antithrombotic agents | Direct factor xa inhibitors)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
This medicine may increase the risk of bleeding.
Edoxaban is an oral anticoagulant from the class of direct factor Xa inhibitors, used for the prevention and treatment of thrombosis and embolism. It works by inhibiting the activity of factor Xa, an enzyme essential for blood clotting, thereby preventing the formation of blood clots.
It is indicated for:
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Prevention of recurrence of these conditions.
Edoxaban is taken orally, once daily, with the dose adjusted based on the patient's weight, kidney function, and concomitant medications.
Side effects may include bleeding (nasal, gastrointestinal, or other types), anemia, nausea, skin rashes, or, rarely, severe allergic reactions. Patients should be monitored for signs of excessive bleeding.
Edoxaban is contraindicated in patients with active bleeding, severe liver impairment, severe coagulopathies, or those taking other anticoagulants. It is important to use it as prescribed by a doctor, and discontinuation should be done cautiously to avoid the risk of thrombosis.